- 03/06/2025 - PHARMANUTRA LAUNCHES THE NEW NUTRITIONAL SUPPLEMENT APPORTAL® BOOST
- 12/05/2025 - THE BOARD OF DIRECTORS APPROVES THE INTERIM MANAGEMENT REPORT AS AT MARCH 31, 2025
- 06/05/2025 - ALLEGATO 3F – APRILE 2025
- 06/05/2025 - PHARMANUTRA S.P.A.: PARTNERSHIP WITH GIRO D’ITALIA
- 22/04/2025 - SHAREHOLDERS' MEETING OF 16/04/2025 - REPORT OF VOTING RESULTS
- 16/04/2025 - ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING OF 16 APRIL 2025
- 09/04/2025 - THE INTERNATIONALISATION PROCESS CONTINUES
- 08/04/2025 - ALLEGATO 3F – MARZO 2025
- 02/04/2025 - NEWS AND UPDATES ON FOREIGN MARKETS
- 26/03/2025 - FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING
- 26/03/2025 - ANOTHER YEAR WITH FERNANDO ALONSO
- 24/03/2025 - SUCROSOMIAL IRON® MENTIONED IN THE GUIDELINES OF THE WORLD HEALTH ORGANISATION
- 21/03/2025 - RENEWED THE PARTNERSHIP WITH AF CORSE
- 19/03/2025 - PHARMANUTRA S.P.A. TO ATTEND THE EURONEXT STAR CONFERENCE 2025
- 17/03/2025 - CLARIFICATION NOTE ON THE PRESS RELEASE OF 14.03.2025
- 14/03/2025 - THE BOARD OF DIRECTORS APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2024
- 13/01/2025 - 2024 PRELIMINARY SALES FIGURES
- 18/12/2024 - 2025 CORPORATE EVENTS CALENDAR PUBLICATION
- 25/11/2024 - DISTRIBUTION AGREEMENT FOR SIDERAL® PRODUCTS SIGNED IN CANADA
- 18/11/2024 - FIRST SIGNIFICANT SALES RESULTS IN CHINA
- 11/11/2024 - PHARMANUTRA S.P.A.: THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT SEPTEMBER 30, 2024
- 04/11/2024 - PHARMANUTRA S.P.A. APPLIES ITS PROPRIETARY SUCROSOMIAL® TECHNOLOGY TO VITAMINS AND LAUNCHES NEW SIDEVIT® LINE
- 29/10/2024 - AGREEMENT WITH AN INTERNATIONAL ADVISOR IN ORDER TO DEFINE A DEVELOPMENT PLAN FOR PHARMANUTRA USA
- 09/09/2024 - BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2024
- 03/09/2024 - LAUNCH OF TWO SIDERAL® PRODUCTS IN GERMANY
- 24/07/2024 - SIGNIFICANT SALES AND MARKET POSITIONING RESULTS IN THE ITALIAN NUTRACEUTICAL MARKET
- 05/07/2024 - EFFECTIVENESS OF THE MERGER BY INCORPORATION
- 22/06/2024 - INTERNAL DEALING COMMUNICATION
- 18/06/2024 - THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO
- 13/06/2024 - A NEW STUDY HIGHLIGHTS THE EFFICACY, SUPERIORITY AND IMPROVED TOLERABILITY OF SIDERAL® COMPARED TO CONVENTIONAL IRON SUPPLEMENT TREATMENTS
- 12/06/2024 - INITIATION OF SHARE BUY-BACK PROGRAM
- 13/05/2024 - PHARMANUTRA S.P.A. THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT 31 MARCH2024 AND THE 2023 SUSTAINABILITY REPORT
- 15/04/2024 - THE MERGER BY INCORPORATION INTO PHARMANUTRA S.P.A. OF JUNIA PHARMA S.R.L. AND ALESCO S.R.L. HAS BEEN APPROVED
- 15/03/2024 - PHARMANUTRA S.P.A.: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2023
- 26/02/2024 - APPROVAL OF THE MERGER PLAN
- 11/01/2024 - EURO 100 MILLION IN REVENUE REACHED IN THE YEAR OF ITS 20TH ANNIVERSARY SINCE ESTABLISHMENT
- 08/01/2024 - LOSS OF SME STATUS
- 21/12/2023 - PUBLICATION OF THE 2024 CORPORATE EVENTS CALENDAR
- 08/11/2023 - MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER’S SECURITIES
- 06/11/2023 - BOD APPROVES INTERIM MANAGEMENT REPORT AS AT 30/09/2023
- 10/10/2023 - PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM
- 03/10/2023 - PHARMANUTRA S.P.A.: FIRST SALES ON THE US MARKET
- 19/09/2023 - PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2023
- 12/09/2023 - POLICY FOR THE MANAGEMENT OF THE DIALOGUE WITH ALL SHAREHOLDERS OF PHARMANUTRA S.P.A.
- 11/09/2023 - PHARMANUTRA S.P.A.: THE BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2023
- 30/08/2023 - PHARMANUTRA S.P.A.: LIPOCET (CETILAR®) GETS THE GREEN LIGHT TO BE CLASSIFIED AS A 'NOVEL FOOD' ALSO IN THE UK
- 03/08/2023 - PHARMANUTRA S.P.A.: CETILAR® WITH MARCELL JACOBS HEADING FOR PARIS 2024
- 17/07/2023 - PHARMANUTRA S.P.A.: THE BOARD OF DIRECTORS APPROVES THE 2022 SUSTAINABILITY REPORT AND APPOINTS THE SUSTAINABILITY GOVERNANCE
- 11/07/2023 - PHARMANUTRA S.P.A.: CETILAR® IS RECONFIRMED AS MAIN SPONSOR OF THE PISA SPORTING CLUB FOR 2023-2024
- 26/05/2023 - PHARMANUTRA S.P.A.: CETILAR® SIDE BY SIDE WITH FERNANDO ALONSO
- 08/05/2023 - PHARMANUTRA S.P.A.: BOARD OF DIRECTORS APPROVES INTERIM REPORT TO 31 MARCH 2023
- 12/04/2023 - PHARMANUTRA SIGNS THREE NEW AGREEMENTS FOR THE FOREIGN DISTRIBUTION OF SIDERAL® PRODUCTS
- 16/03/2023 - PHARMANUTRA: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2022
- 21/02/2023 - PHARMANUTRA THE STRATEGIC GUIDELINES FOR THE NEXT YEARS WERE PRESENTED AT THE INVESTOR'S DAY
- 08/02/2023 - PHARMANUTRA PARTNERS WITH FERRARI TO FACE THE CHALLENGES OF THE NEW LE MANS HYPERCAR 499P
- 24/01/2023 - INTEGRATION OF THE 2023 CORPORATE EVENTS CALENDAR
- 12/01/2023 - PUBLICATION OF THE 2023 CORPORATE EVENTS CALENDAR
- 04/01/2023 - NEW DISTRIBUTION AGREEMENTS IN INDONESIA, KUWAIT AND MEXICO
- 12/12/2022 - NEW COMPANY PHARMANUTRA U.S.A. CORP. ESTABLISHED FOR DISTRIBUTION IN THE UNITED STATES
- 05/12/2022 - PHARMANUTRA S.P.A. COMPLETES AKERN S.R.L. ACQUISITION
- 15/11/2022 - PHARMANUTRA PARTNERS WITH THE LUNA ROSSA PRADA PIRELLI TEAM FOR THE 37TH EDITION OF THE AMERICA’S CUP
- 07/11/2022 - BOARD OF DIRECTORS APPROVES INTERIM MANAGEMENT REPORT AS AT 30 SEPTEMBER 2022
- 15/09/2022 - PHARMANUTRA S.P.A. LAUNCHES NEW PRODUCTS CETILAR® ORO AND APPORTAL® VITAL
- 14/09/2022 - HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2022
- 05/09/2022 - THE BOD APPROVES THE FIRST HALF FINANCIAL REPORT AS AT 30/06/2022 AND THE GROUP’S FIRST SUSTAINABILITY REPORT
- 04/08/2022 - BUY-BACK REPORT JULY 2022
- 26/07/2022 - PHARMANUTRA S.P.A.: FIRST ACQUISITION CLOSING OF AKERN S.R.L. FINALISED
- 06/07/2022 - BUY-BACK REPORT JUNE 2022
- 17/06/2022 - GOLDEN POWER NOTIFICATION FILED IN CONNECTION WITH THE ACQUISITION OF 100% OF AKERN S.R.L.
- 15/06/2022 - SIGNING OF THE AGREEMENT FOR THE ACQUISITION OF 100% OF AKERN S.R.L.
- 08/06/2022 - BUY-BACK REPORT MAY 2022
- 27/05/2022 - PUBLICATION OF THE SHAREHOLDERS’ MEETINGS MINUTES HELD ON 27/04/2022
- 16/05/2022 - PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM
- 12/05/2022 - INTERIM FINANCIAL REPORT AS OF 31 MARCH 2022 NOW AVAILABLE
- 09/05/2022 - PHARMANUTRA S.P.A.: INTERIM REPORT AS AT 31 MARCH 2022
- 02/05/2022 - SYNTHETIC REPORT ON VOTING RESULTS OF THE SHAREHOLDERS’ MEETINGS 27/04/2022
- 27/04/2022 - RESOLUTIONS OF THE SHAREHOLDERS' MEETING OF 27/04/2022
- 11/04/2022 - BUY-BACK REPORT MARCH 2022
- 31/03/2022 - NOTICE OF PUBLICATIONOF THE 2021 ANNUAL FINANCIAL REPORT
- 18/03/2022 - PHARMANUTRA S.P.A.: FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING
- 18/03/2022 - PHARMANUTRA S.P.A.: THE BOARD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2021
- 08/03/2022 - BUY-BACK REPORT FEBRUARY 2022
- 23/02/2022 - MODIFICATION OF THE 2022 CORPORATE EVENTS CALENDAR
- 14/02/2022 - THE EUROPEAN UNION AUTHORISES MARKETING OF CFAS AS A NOVEL FOOD
- 07/02/2022 - BUY-BACK REPORT JANUARY 2022
- 31/01/2022 - PHARMANUTRA S.P.A. CONFIRMS STRONG SALES INCREASE
- 24/01/2022 - PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM
- 17/01/2022 - PHARMANUTRA S.P.A.: NEW LICENCE GRANTED IN THE U.S.A.
- 14/01/2022 - PUBLICATION OF THE 2022 CORPORATE EVENTS CALENDAR
- 13/01/2022 - PHARMANUTRA S.P.A. STRENGTHENS PRESENCE ON TAIWANESE MARKET
- 02/12/2021 - PHARMANUTRA S.P.A. JOINS THE “MSCI WORLD SMALL CAP” AND “FTSE ITALIA MID CAP” INDICES
- 25/11/2021 - PHARMANUTRA GROUP: THREE NEW PATENTS RELEASED
- 16/11/2021 - NEW INTERNATIONAL AGREEMENT FOR THE DISTRIBUTION OF SIDERAL® IN ARGENTINA
- 12/11/2021 - INTERIM FINANCIAL REPORT AS OF 30 SEPTEMBER 2021
- 08/11/2021 - BOARD OF DIRECTORS APPROVES INTERIM MANAGEMENT REPORT AS AT 30 SEPTEMBER 2021
- 25/10/2021 - PHARMANUTRA S.P.A.: ALESCO SUBSIDIARY OBTAINS PATENT FOR THE NEW SUCROSOMIAL® BERBERINE
- 21/10/2021 - PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PROCESS PATENT IN INDIA
- 13/10/2021 - NEW DISTRIBUTION AGREEMENTS WITH AMERICAN TAIWAN BIOPHARM CO. AND ARGON DRUG STORE
- 04/10/2021 - PHARMANUTRA S.P.A. CONFIRMS GROWTH TREND IN ITALY AND STRONG RECOVERY ON INTERNATIONAL MARKETS
- 13/09/2021 - HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2021
- 06/09/2021 - BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2021
- 25/08/2021 - PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PATENT IN CHINA
- 21/07/2021 - EFSA IN FAVOUR OF AUTHORISING LIPOCET (CETILAR®) AS A NOVEL FOOD
- 29/06/2021 - BOD APPROVES THE NEW PROCEDURE RELATING TO TRANSACTIONS WITH RELATED PARTIES
- 10/06/2021 - AGREEMENT FOR THE DISTRIBUTION OF SIDERAL® IN GERMANY SIGNED WITH FRESENIUS KABI
- 07/06/2021 - SALES FIGURES FOR MAY 2021: OVER 300,000 UNITS PER MONTH SOLD
- 26/05/2021 - PUBLICATION OF SHAREHOLDERS’ MEETINGS MINUTES 26/04/2021
- 10/05/2021 - PHARMANUTRA S.P.A.: BOARD APPROVES INTERIM MANAGEMENT REPORT AS OF 31ˢᵗ MARCH 2021
- 03/05/2021 - PHARMANUTRA S.P.A.: ITALIAN MARKET DOUBLE FIGURE GROWTH ONCE AGAIN
- 29/04/2021 - SYNTHETIC REPORT ON VOTING RESULTS OF THE ORDINARY SHAREHOLDERS’ MEETINGS HELD ON APRIL 26TH 2021
- 26/04/2021 - PHARMANUTRA S.P.A.: ORDINARY SHAREHOLDERS’ MEETING OF 26ᵗʰ APRIL 2021
- 19/04/2021 - PHARMANUTRA S.P.A. LAUNCHES ITS NEW SIDERAL® MED
- 07/04/2021 - A NEW STUDY DEMONSTRATES THE EFFECTS OF USING APPORTAL® IN PATIENTS SUFFERING FROM CHRONIC COVID SYNDROME
- 01/04/2021 - FILING OF THE REPORT ON THE REMUNERATION POLICY
- 31/03/2021 - NEW FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING
- 25/03/2021 - FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING
- 22/03/2021 - PHARMANUTRA SPA: BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AS AT 31ST DECEMBER 2020
- 08/03/2021 - MODIFICATION OF THE 2021 CORPORATE EVENTS CALENDAR
- 29/01/2021 - PUBLICATION OF THE 2021 CORPORATE EVENTS CALENDAR
- 18/01/2021 - PHARMANUTRA S.P.A. APPOINTS A SUPERVISORY BODY
- 22/12/2020 - CETILAR® PATCH AND CETILAR® TAPE CERTIFIED CLASS 2A MEDICAL DEVICES
- 11/12/2020 - BORSA ITALIANA ORDERS ADMISSION OF THE ORDINARY SHARES OF PHARMANUTRA TO TRADING ON THE MTA - STAR SEGMENT
- 11/12/2020 - THE INFORMATION PROSPECTUS ON ADMISSION TO TRADING ON THE MTA - STAR SEGMENT HAS BEEN PUBLISHED
- 11/12/2020 - CONSOB APPROVES THE INFORMATION PROSPECTUS FOR ADMISSION TO TRADING ON MTA - STAR SEGMENT
- 01/12/2020 - PHARMANUTRA S.P.A.: NEW DISTRIBUTION AGREEMENT FOR BRAZIL
- 18/11/2020 - PHARMANUTRA S.P.A.: NEW INTERNATIONAL DISTRIBUTION AGREEMENTS
- 11/11/2020 - PHARMANUTRA S.P.A.: REGISTRATION OF THE BRANDS CETILAR® AND SIDERAL® GRANTED IN THE USA
- 09/11/2020 - PHARMANUTRA S.P.A.: CONSOLIDATED FINANCIAL REPORT AS AT 30TH SEPTEMBER 2020
- 03/11/2020 - PHARMANUTRA S.P.A. PRESENTS A NEW CETILAR® LINE PRODUCT
- 27/10/2020 - MTA STAR LISTING PROCESS: AMENDMENT TO THE EXISTING SHAREHOLDERS’ AGREEMENT AND COMMITMENT TO THE 36 MONTHS LOCK UP
- 23/10/2020 - THE MTA STAR LISTING PROCESS: BOD OF PHARMANUTRA S.P.A.
- 13/10/2020 - ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING AND BOARD OF DIRECTORS’ MEETING DOWNSTREAM OF THE SHAREHOLDERS’ MEETING
- 21/09/2020 - LAUNCH OF THE MTA STAR SEGMENT LISTING APPROVED BY THE BOARD OF DIRECTORS
- 14/09/2020 - EXCEPTIONAL RESULTS IN THE FIRST HALF OF 2020. DOUBLE DIGIT GROWTH.
- 10/09/2020 - PHARMANUTRA S.P.A.: NEW DISTRIBUTION AGREEMENT SIGNED FOR BOLIVIA
- 08/09/2020 - NEW DISTRIBUTION AGREEMENT SIGNED BETWEEN ALESCO AND DELTAGEN UK – ATURA
- 27/08/2020 - THE GROUP KEEPS ON GROWING UNLIKE THE ITALIAN MARKET
- 20/07/2020 - PHARMANUTRA CELEBRATES THREE YEARS SINCE BEING LISTED ON THE AIM ITALIA MARKET
- 14/07/2020 - PHARMANUTRA S.P.A.: REVENUE INCREASES +17% IN THE FIRST HALF OF 2020
- 12/06/2020 - AGREEMENT RELATED TO THE PATENT BOX REGIME SIGNED WITH THE REVENUE OFFICE
- 25/05/2020 - PHARMANUTRA S.P.A. TAKES PART IN THE AIM ITALIA CONFERENCE 2020
- 07/05/2020 - CETILAR® OBTAINS PLAY SURE DOPING FREE CERTIFICATION
- 29/04/2020 - PHARMANUTRA S.P.A.:NEW DISTRIBUTION AGREEMENTS IN EUROPE, ASIA AND LATIN AMERICA.
- 27/04/2020 - PHARMANUTRA S.P.A.: ORDINARY SHAREHOLDERS’ MEETING OF 27TH APRIL 2020
- 16/04/2020 - PRESENTATION OF PROPOSALS FOR APPOINTMENTS TO THE BOARD OF DIRECTORS OF PHARMANUTRA S.P.A.
- 15/04/2020 - PHARMANUTRA S.P.A.: PFIZER INVESTS IN SUCROSOMIAL® TECHNOLOGY
- 09/04/2020 - PHARMANUTRA S.P.A.: NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETING
- 06/04/2020 - PHARMANUTRA S.P.A.: PROPOSAL TO AUTHORISE THE PURCHASE AND DISPOSAL OF TREASURY STOCK
- 03/04/2020 - PHARMANUTRA S.P.A.: FIGURES FOR THE FIRST QUARTER 2020 GROWING
- 25/03/2020 - PHARMANUTRA S.P.A. OBTAINS APPROVAL FOR TWO NEW PATENTS IN INDIA AND UNITED STATES
- 23/03/2020 - PHARMANUTRA S.P.A.: DOUBLE FIGURE GROWTH CONTINUES
- 10/03/2020 - PHARMANUTRA S.P.A SUPPORTING THE NATIONAL HEALTH SERVICE IN THIS EMERGENCY
- 07/02/2020 - NEW AGREEMENTS FOR THE DISTRIBUTION OF SIDERAL® IN MEXICO, THE CZECH REPUBLIC AND SLOVAKIA
- 03/02/2020 - PHARMANUTRA S.P.A.: CORPORATE EVENTS CALENDAR 2020
- 08/01/2020 - PHARMANUTRA S.P.A. ENGAGES MEDIOBANCA S.P.A. AS SPECIALIST
- 08/01/2020 - FOOD SUPPLEMENT MARKET IS GROWING IN ITALY AND SIDERAL® FORTE 20 CAPSULES IS THE MOST SOLD NUTRITIONAL SUPPLEMENT IN THE COUNTRY.
- 19/12/2019 - MEDIOBANCA – BANCA DI CREDITO FINANZIARIO S.P.A. STARTS SHARE COVERAGE
- 28/11/2019 - ONGOING INTERNATIONAL EXPANSION FOR THE GROUP, STRENGTHENED BY NEW PATENTS APPROVED
- 19/11/2019 - JUNIA PHARMA SRL LAUNCHES BLEFARENE BABY ON THE MARKET
- 12/11/2019 - PHARMANUTRA S.P.A. OBTAINS PATENT FOR A NEW COMPOSITION USED FOR TREATING CARDIOVASCULAR DISEASES
- 08/11/2019 - PHARMANUTRA WAS EXHIBITING AT CPHI WORLDWIDE 2019 IN FRANKFURT
- 05/11/2019 - PHARMANUTRA OBTAINS THE SOLID IRON PATENT FOR THE USA
- 22/10/2019 - PHARMANUTRA AT THE AIM ITALIA CONFERENCE DRIVEN BY THE POSITIVE ANALYST FORECASTS
- 17/09/2019 - PHARMANUTRA S.P.A.: RESULTS OF THE FIRST SEMESTER CONFIRM GROWTH IN DOUBLE FIGURES
- 10/09/2019 - PHARMANUTRA S.P.A. NEW AGREEMENT SIGNED WITH WERT PHILIPPINES FOR THE SIDERAL® RANGE
- 28/08/2019 - NEW AGREEMENT FOR THE DISTRIBUTION OF THE SIDERAL LINE IN TAIWAN
- 02/08/2019 - HISTORICAL MONTH-BASED SALES RECORD IN ITALY
- 29/07/2019 - ANTICIPATED INFORMATION ON THE PRELIMINARY CONSOLIDATED REVENUES OF THE FIRST HALF OF 2019
- 16/07/2019 - PHARMANUTRA S.P.A., RESULTS COME FROM RESEARCH
- 05/07/2019 - CETILAR® ONCE AGAIN THE MAIN SPONSOR OF PARMA CALCIO FOR THE 2019/2020 SEASON
- 12/06/2019 - PHARMANUTRA: SALES NETWORK EVOLUTION AND NEW COMMERCIAL STRATEGIES
- 05/06/2019 - THE INTERNATIONAL EXPANSION OF THE SIDERAL® LINE CONTINUES
- 29/05/2019 - NOTIFICATION PURSUANT TO ARTICLE 17 OF THE AIM ITALIA ISSUERS REGULATIONS
- 10/05/2019 - CO-OPTATION OF A NEW ADMINISTRATOR
- 06/05/2019 - NEW INTERNATIONAL AGREEMENTS FOR THE CETILAR® LINE
- 23/04/2019 - JORDAN JOINS THE PHARMANUTRA PARTNER COUNTRIES
- 16/04/2019 - NOTIFICATION PURSUANT TO ARTICLE 17 OF THE AIM ITALIA ISSUERS REGULATIONS
- 16/04/2019 - NEW TRANSACTION BETWEEN SHAREHOLDERS
- 16/04/2019 - RESIGNATION OF A BOARD MEMBER
- 16/04/2019 - CLARIFICATION REGARDING THE 2018 DIVIDEND
- 16/04/2019 - SHAREHOLDERS' MEETING OF 15.04.2019
- 18/03/2019 - NEW INTERNATIONAL AGREEMENTS FOR THE DISTRIBUTION OF CETILAR® AND ULTRAMAG®
- 13/03/2019 - PHARMANUTRA DRAFT FINANCIAL STATEMENTS AND CONSOLIDATED FINANCIAL STATEMENTS AT 31.12.2018
- 12/03/2019 - THE 7TH EDITION OF THE INTERNATIONAL MULTIDISCIPLINARY COURSE ON IRON DEFICIENCY IN ROME
- 21/02/2019 - PHARMANUTRA SIGNS TWO NEW AGREEMENTS FOR THE DISTRIBUTION OF SUCROSOMIAL IRON IN GREECE AND UKRAINE
- 15/01/2019 - PHARMANUTRA SIGNS AN AGREEMENT WITH TRIGEN PHARMA INTERNATIONAL FOR THE DISTRIBUTION OF SIDERAL® PRODUCTS IN PAKISTAN
- 10/01/2019 - PHARMANUTRA: CORPORATE EVENTS CALENDAR 2019
- 20/12/2018 - PHARMANUTRA SIGNS AN IMPORTANT AGREEMENT TO DISTRIBUTE THE CETILAR® LINE IN THAILAND, OPENING UP THE SOUTH EAST ASIAN MARKET
- 14/12/2018 - AIM ITALY: PHARMANUTRA IN THE TOP 10 FOR PERFORMANCE AND CAPITALISATION
- 10/12/2018 - NEW AREAS OF APPLICATION RECOGNISED FOR SUCROSOMIAL IRON
- 04/12/2018 - PHARMANUTRA JOINS FARMINDUSTRIA
- 21/11/2018 - THE GROWTH TREND CONTINUES IN THE FIRST 9 MONTHS OF 2018: SALES ABROAD EXCEED SALES IN ITALY
- 05/11/2018 - FURTHER ACKNOWLEDGMENTS FOR SUCROSOMIAL IRON®
- 08/10/2018 - NEW RECOGNITIONS TO SUCROSOMIAL IRON®
- 04/10/2018 - NOTICE PURSUANT TO ARTICLE 17 OF AIM ITALIA ISSUER REGULATION
- 01/10/2018 - AN AGREEMENT HAS BEEN SIGNED WITH FRESENIUS KABI FOR THE DISTRIBUTION OF SUCROSOMIAL® IRON BASED PRODUCTS IN SWITZERLAND
- 26/09/2018 - PHARMANUTRA S.P.A.: THE RESULTS OF THE FIRST HALF CONFIRM A DOUBLE-DIGIT GROWTH
- 13/09/2018 - PHARMANUTRA GROUP LAUNCHES FOUR NEW PRODUCTS
- 30/08/2018 - PHARMANUTRA GROUP IS STILL GROWING ON THE ITALIAN MARKET
- 26/07/2018 - PHARMANUTRA: REVENUES FOR THE FIRST HALF OF 2018 UP BY 20%. THE GROUP STRENGTHENS ITS INTERNATIONAL PRESENCE
- 18/07/2018 - PHARMANUTRA: GROWTH IN BUSINESS AND VALUE ONE YEAR FROM LISTING ON THE STOCK EXCHANGE
- 11/07/2018 - ULTRAMAG: SUCROSOMIAL TECHNOLOGY REVOLUTIONISES THE MAGNESIUM MARKET
- 05/07/2018 - PHARMANUTRA TAKES CENTRE STAGE AT THE “HEALTHCARE FORUM” AT THE BORSA ITALIANA
- 04/07/2018 - PHARMANUTRA PARTICIPATES IN THE "HEALTH CARE FORUM" IN BORSA ITALIANA
- 03/07/2018 - PHARMANUTRA: FRANCESCO SARTI APPOINTED CHIEF FINANCIAL OFFICER OF THE GROUP
- 28/06/2018 - PHARMANUTRA: NEW SALES RECORD IN MAY
- 28/05/2018 - NEW COMMERCIAL AGREEMENTS SIGNED FOR THE DISTRIBUTION OF SUCROSOMIAL® IRON ABROAD
- 23/04/2018 - PHARMANUTRA: SHAREHOLDERS' MEETING OF 23 APRIL 2018
- 11/04/2018 - 6TH INTERNATIONAL MULTIDISCIPLINARY COURSE ON IRON DEFICIENCY (IMCID)
- 06/04/2018 - PHARMANUTRA OBTAINS A PATENT FOR CETILAR® RM
- 27/03/2018 - PHARMANUTRA: SUCROSOMIAL® IRON CHOSEN AS PRODUCT OF THE YEAR BY ISRAELI CONSUMERS
- 20/03/2018 - PHARMANUTRA: THE BOARD OF DIRECTORS APPROVES THE DRAFT SEPARATE AND CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEAR ENDED 31 DECEMBER 2017
- 02/03/2018 - PHARMANUTRA: HIGHLY SUCCESSFUL FIRST EDITION OF THE CONVENTION DEDICATED TO INTERNATIONAL PARTNERS
- 22/02/2018 - PHARMANUTRA: 2017 PRELIMINARY RESULTS DOUBLE-DIGIT REVENUE AND MARGIN GROWTH
- 18/10/2017 - COMMUNICATION OF CHANGING SOCIAL CAPITAL
